TP53 and glioblastoma: Relatedly, we found a significant difference in the overall survival of GBM treated with CCRT plus bevacizumab compared with GBM treated with CCRT alone that was dependent on the different p53 codon 72 genotypes, with both the Arg/Arg and Pro/Arg genotypes being associated with a better prognosis than the Pro/Pro genotype.